Key result
The TYRX absorbable antibacterial envelope is associated with cost-effectiveness ratios below USA and European benchmarks in selected patients at increased risk of CIED infection.
Why the study?
CIED infections and related adverse outcomes have a major financial impact on healthcare systems, necessitating evaluation of the economic profile of the TYRX absorbable antibacterial envelope.
Does the TYRX absorbable antibacterial envelope improve cost-effectiveness compared to standard of care in patients undergoing CIED procedures?
Does the TYRX absorbable antibacterial envelope improve cost-effectiveness compared to standard of care in patients undergoing CIED procedures?
Answers are grounded in this paper and cite their sources.
The TYRX antibacterial envelope provides economic value and is cost-effective according to USA and European benchmarks for patients at high risk of CIED infection.
The occurrence of cardiac implantable electronic devices (CIED) infections and related adverse outcomes have an important financial impact on the healthcare system, with hospitalization length of stay (2-3 weeks on average) being the largest cost driver, including the cost of device system extraction and device replacement accounting for more than half of total costs. In the recent literature, the economic profile of the TYRX™ absorbable antibacterial envelope was analysed taking into account both randomized and non-randomized trial data. Economic analysis found that the envelope is associated with cost-effectiveness ratios below USA and European benchmarks in selected patients at increased risk of infection. Therefore, the TYRX™ envelope, by effectively reducing CIED infections, provides value according to the criteria of affordability currently adopted by USA and European healthcare systems.
No takes yet. Share an insight, caveat, or question.
Boriani et al. (2021) conducted a review in Cardiac implantable electronic device (CIED) infections. TYRX antibacterial envelope vs. Standard of care was evaluated on Infection resulting in system extraction or revision, long-term antibiotic therapy with infection recurrence, or death, within 12 months (HR 0.60, 95% CI 0.36-0.98, p=0.04). The TYRX absorbable antibacterial envelope is associated with cost-effectiveness ratios below USA and European benchmarks in selected patients at increased risk of CIED infection.
Synapse has enriched 10 related papers. Consider them for comparative context: